Harvard's Gregory Verdine has big ambitions for his miniprotein 'braces' — and now $107M to guide them to the clinic

Nicole DeFeudis

Editor

Harvard scientist Gregory Verdine’s mission has always been clear: drug the undruggable. He’s now one step closer, with $107 million in the bank to bring …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Harvard's Gregory Verdine has big ambitions for his miniprotein 'braces' — and now $107M to guide them to the clinic

Nicole DeFeudis

Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Exclusive: Bucking gene-editing downturn, Tune raises $175M to bring epigenetic editing to clinic

Biogen offers to buy out struggling neuro partner Sage Therapeutics

Chasing the next wave of obesity drugs, Metsera files for an IPO

Four biotechs emerge with $800M and in-licensed assets on Friday

Exclusive: Moderna's former top scientist has a new startup using AI to improve mRNA therapies

Updated: CDER Director Patrizia Cavazzoni to step down ahead of Trump presidency

Har­vard's Gre­go­ry Ver­dine has big am­bi­tions for his minipro­tein 'braces' — and now $107M to guide them to the clin­ic

Editor

Sign up to read this article for free.

more like this

Bachem

Bubendorf, BL, Switzerland

Harvard's Gregory Verdine has big ambitions for his miniprotein 'braces' — and now $107M to guide them to the clinic